[go: up one dir, main page]

KR20020012215A - 지질 매트릭스-약물 컨쥬게이트로부터 조제된 활성성분의투여 제어를 위한 약물 운반체 - Google Patents

지질 매트릭스-약물 컨쥬게이트로부터 조제된 활성성분의투여 제어를 위한 약물 운반체 Download PDF

Info

Publication number
KR20020012215A
KR20020012215A KR1020017014236A KR20017014236A KR20020012215A KR 20020012215 A KR20020012215 A KR 20020012215A KR 1020017014236 A KR1020017014236 A KR 1020017014236A KR 20017014236 A KR20017014236 A KR 20017014236A KR 20020012215 A KR20020012215 A KR 20020012215A
Authority
KR
South Korea
Prior art keywords
active ingredient
particulate active
drug
ingredient carrier
ldc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020017014236A
Other languages
English (en)
Korean (ko)
Inventor
레이너 헬무트 뮐러
카스텐 올브리치
Original Assignee
파르마솔 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19920908A external-priority patent/DE19920908A1/de
Priority claimed from DE19964085A external-priority patent/DE19964085A1/de
Application filed by 파르마솔 게엠베하 filed Critical 파르마솔 게엠베하
Publication of KR20020012215A publication Critical patent/KR20020012215A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020017014236A 1999-05-07 2000-05-08 지질 매트릭스-약물 컨쥬게이트로부터 조제된 활성성분의투여 제어를 위한 약물 운반체 Withdrawn KR20020012215A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19920908A DE19920908A1 (de) 1999-05-07 1999-05-07 Arzneistoffträger zur kontrollierten Wirkstoffapplikation hergestellt aus Lipidmatrix-Arzneistoffkonjugaten (LAK-Partikel)
DE19920908.1 1999-05-07
DE19964085.8 1999-12-27
DE19964085A DE19964085A1 (de) 1999-12-27 1999-12-27 Arzneistoffträgr zur kontrollierten Wirkstoffapplikation hergestellt aus Lipidmatrix-Arzneistoffkonjugaten (LAK-Partikel)
PCT/EP2000/004111 WO2000067800A2 (fr) 1999-05-07 2000-05-08 Excipient pour l'administration controlee de principe actif, produit a partir de conjugues matrice lipidique-substance pharmaceutique

Publications (1)

Publication Number Publication Date
KR20020012215A true KR20020012215A (ko) 2002-02-15

Family

ID=26053253

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017014236A Withdrawn KR20020012215A (ko) 1999-05-07 2000-05-08 지질 매트릭스-약물 컨쥬게이트로부터 조제된 활성성분의투여 제어를 위한 약물 운반체

Country Status (11)

Country Link
US (1) US6770299B1 (fr)
EP (1) EP1176984B1 (fr)
JP (1) JP2002544177A (fr)
KR (1) KR20020012215A (fr)
AU (1) AU4563100A (fr)
BR (1) BR0010356A (fr)
CA (1) CA2372461A1 (fr)
DE (1) DE50013950D1 (fr)
MX (1) MXPA01011347A (fr)
TR (1) TR200103187T2 (fr)
WO (1) WO2000067800A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680087A1 (fr) * 2003-10-31 2006-07-19 Teva Pharmaceutical Industries Limited Nanoparticules pour la delivrance de medicaments
CA2549966A1 (fr) * 2003-12-24 2005-07-07 Ltt Bio-Pharma Co., Ltd. Nanoparticules contenant des medicaments, procede de production, et preparation pour administration parenterale obtenue a partir de la nanoparticule
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20070254037A1 (en) * 2004-12-15 2007-11-01 Youri Popowski Methods and Compositions for the Treatment of Cell Proliferation
EP1674081A1 (fr) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Préparation de nano-particules à bases lipides en utilisant une centrifuge duale et asymétrique
CA2669392C (fr) 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocristaux pour une utilisation dans des formulations cosmetiques topiques et leur procede de fabrication
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US20090053268A1 (en) * 2007-08-22 2009-02-26 Depablo Juan J Nanoparticle modified lubricants and waxes with enhanced properties
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
EP2393472B1 (fr) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Promédicaments amphiphiles
EP2229936B1 (fr) * 2009-03-09 2015-05-06 PharmaSol GmbH Formules de testostérone de taille nano pour une meilleure biodisponibilité
WO2012059936A1 (fr) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Compositions pharmaceutiques destinées à l'administration de médicaments colloïdaux
CN104127387A (zh) * 2014-02-21 2014-11-05 杭州长典医药科技有限公司 奥美拉唑钠特种超细粉体冻干制剂及其制备方法
BE1023491B1 (nl) * 2015-10-06 2017-04-06 Nutri-Ad International Nv Voedingsadditief voor gevogelte
KR20210142152A (ko) * 2019-03-22 2021-11-24 인티그레이티드 나노테라퓨틱스 아이엔씨. 스캐폴드 모이어티로부터 제조된 지질 접합체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5907030A (en) * 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

Also Published As

Publication number Publication date
TR200103187T2 (tr) 2002-04-22
EP1176984A2 (fr) 2002-02-06
BR0010356A (pt) 2002-02-13
MXPA01011347A (es) 2004-06-03
AU4563100A (en) 2000-11-21
US6770299B1 (en) 2004-08-03
WO2000067800A2 (fr) 2000-11-16
JP2002544177A (ja) 2002-12-24
DE50013950D1 (de) 2007-02-22
CA2372461A1 (fr) 2000-11-16
WO2000067800A3 (fr) 2001-05-10
EP1176984B1 (fr) 2007-01-10

Similar Documents

Publication Publication Date Title
Pardeshi et al. Solid lipid based nanocarriers: An overview/Nanonosaci na bazi cvrstih lipida: Pregled
Fang et al. Nanostructured lipid carriers (NLCs) for drug delivery and targeting
Tsai et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations
Lee et al. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles
Mudshinge et al. Nanoparticles: Emerging carriers for drug delivery
KR20020012215A (ko) 지질 매트릭스-약물 컨쥬게이트로부터 조제된 활성성분의투여 제어를 위한 약물 운반체
Yadav et al. Nanosuspension: A promising drug delivery system
Rampaka et al. Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl
Khatak et al. Recent techniques and patents on solid lipid nanoparticles as novel carrier for drug delivery
Shah et al. Lipid nanocarriers: Preparation, characterization and absorption mechanism and applications to improve oral bioavailability of poorly water-soluble drugs
Joyce et al. Comparison across three hybrid lipid-based drug delivery systems for improving the oral absorption of the poorly water-soluble weak base cinnarizine
Zhao Self-nanoemulsifying drug delivery systems (SNEDDS) for the oral delivery of lipophilic drugs
Pandey Solid lipid nanoparticles: a multidimensional drug delivery system
JP2023552815A (ja) 脂質ナノ粒子を調製するためのハイスループット方法及びその使用
Poovi et al. Solid lipid nanoparticles and nanostructured lipid carriers: a review of the effect of physicochemical formulation factors in the optimization process, different preparation technique, characterization, and toxicity
CN103228266B (zh) 三元混合物制剂
Kulkarni et al. Stabilization of lipid vesicles: Upcoming strategic insights for product development
Küçüktürkmen et al. A new approach for drug targeting to the central nervous system: Lipid nanoparticles
Cao et al. Combretastatin A4-loaded poly (lactic-co-glycolic acid)/soybean lecithin nanoparticles with enhanced drug dissolution rate and antiproliferation activity
JP5221126B2 (ja) 水溶性物質で表面修飾された微粒子の製造方法
CN101322719B (zh) 一种三氧化二砷固体脂质纳米粒及其制剂
Nam et al. Multifactorial drug carrier system bringing both chemical and physical therapeutics to the treatment of tumor heterogeneity
Sinha et al. Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia
CN112870178B (zh) 菲并吲哚里西啶生物碱衍生物固体脂质纳米粒组合物
KR102723533B1 (ko) 암포테리신 b를 함유하고, 안정성이 개선된 리포좀 제제의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20011107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid